Publications by authors named "K Ejiri"
Background: We sought to evaluate the associations of chest pain and dyspnea with the long-term risk of cardiovascular disease including coronary disease, heart failure, atrial fibrillation, and stroke.
Methods: In 13,200 participants without cardiovascular disease in the Atherosclerosis Risk in Communities study (1987-1989), chest pain was categorized into definite angina, possible angina, non-anginal chest pain, and no chest pain using the Rose questionnaire. Dyspnea was categorized into grades 3-4, 2, 1, and 0 by the modified Medical Research Council scale.
Background: Remote monitoring (RM) of cardiac implantable electrical devices (CIEDs) can detect various events early. However, the diagnostic ability of CIEDs has not been sufficient, especially for lead failure. The first notification of lead failure was almost noise events, which were detected as arrhythmia by the CIED.
View Article and Find Full Text PDFArticle Synopsis
- A study aimed to assess a treatment strategy for congenital heart defects in patients with significant pulmonary arterial hypertension (PAH), focusing on identifying those who could undergo a "treat and repair" approach.
- Among 25 patients, 20 successfully underwent defect repair, showing a notable decrease in pulmonary vascular resistance (PVR) and an increase in blood flow ratio after the procedure.
- The results suggest that the "treat and repair" strategy may improve outcomes for patients with congenital heart defects and PAH, with specific pretreatment variables linked to successful repairs.
Background: Some patients with chronic thromboembolic pulmonary hypertension (CTEPH) exhibit exercise intolerance due to reduced cardiac output (CO) even after successful balloon pulmonary angioplasty (BPA). Medical therapy is a potential option for such cases; however, it is unclear which patients necessitate it even after BPA.
Methods: This study included 286 patients with CTEPH who underwent BPA and right heart catheterization 1 year after the final BPA and classified them into no-medication and withdrawal groups.
Article Synopsis
- The study analyzed the effectiveness and safety of five SGLT2 inhibitors across different patient backgrounds, specifically focusing on cardiovascular death and hospitalizations for heart failure as primary outcomes.
- It included data from 21 randomized controlled trials with nearly 100,000 participants, revealing that while most SGLT2 inhibitors had similar efficacy, empagliflozin and dapagliflozin showed lower risks of acute kidney injury compared to sotagliflozin.
- The findings suggest that there are no major differences in safety outcomes among the SGLT2 inhibitors, but empagliflozin may be particularly beneficial for patients without chronic kidney disease, indicating a need for further research.